Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M. S. Fominykh"'
Autor:
A. A. Zhernyakova, I. S. Martynkevich, V. A. Shuvaev, L. B. Polushkina, M. S. Fominykh, V. Yu. Udal’eva, I. I. Zotova, D. I. Shiсhbabaeva, S. V. Voloshin, S. S. Бессмельцев, A. V. Chechetkin, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 12, Iss 2, Pp 30-38 (2017)
Background. Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence (JAK2V617F (JAK2+), MPL (MPL+
Externí odkaz:
https://doaj.org/article/ff4d08c63d6c4263aec7f738cf2269b0
Publikováno v:
Онкогематология, Vol 9, Iss 3, Pp 16-24 (2015)
The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis
Externí odkaz:
https://doaj.org/article/8c2c66c1c464440e9f986cd78550b753
Autor:
M. S. Fominykh, V. A. Shuvaev, I. S. Martynkevich, L. B. Polushkina, V. Yu. Udal’eva, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 11, Iss 2, Pp 37-39 (2016)
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxici
Externí odkaz:
https://doaj.org/article/7eb709681d9f4452b8452457999d58aa
Autor:
S. V. Voloshin, Yu. A. Krivolapov, A. V. Shmidt, V. A. Shuvaev, M. S. Fominykh, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 8, Iss 2, Pp 8-21 (2014)
In this article we present the most up-to-date information about etiology, pathogenesis, diagnostic and treatment principles of primary central nervous system diffuse large B-cell lymphoma. We propose algorithm of diagnosis and treatment based on lit
Externí odkaz:
https://doaj.org/article/da6112ef097c4217bf14ef33dfc36ea5
Autor:
V. A. Shuvaev, M. S. Fominykh, I. S. Martynkevich, V. Y. Udaleva, N. A. Potikhonova, M. N. Zenina, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 8, Iss 4, Pp 7-12 (2014)
At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy inter
Externí odkaz:
https://doaj.org/article/1afb3b8b52094c91856fa9a22ed1a382
Autor:
A. M Radzhabova, S. V Voloshin, I. S Martynkevich, A. A Kuzyaeva, VA. Shuvaev, E. V Motyko, A. Y Kuvshinov, M. S Fominykh, A. V Schmidt, L. B Polushkina, M. P Bakay, S. A Tiranova, M. N Zenina, N. A Potihonova, SA. Kudryashova, V. A Balashova, J. V Chubukina, O. S Uspenskaya, E. V Karyagina, A. N Bogdanov, A. V Chechetkin
Publikováno v:
Genes & Cells. 14:55-61
Detection of FLT3 gene mutations in acute myeloid leukemia is now recognized as an unfavorable factor that affects the disease course, emerging the risk of relapses and overall survival shortening and disease-free survival of patients. The aim of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af4b36307e43e7d49984a402281ca53
https://doi.org/10.23868/201903007
https://doi.org/10.23868/201903007
Autor:
Valery G. Savchenko, Irina Martynkevich, P S Krasikova, S R Goryacheva, E Yu Chelysheva, M S Fominykh, Oleg Shukhov, L Yu Kolosova, A O Abdullaev, Vakhrusheva Mv, Anna Petrova, Anna G. Turkina, Anastasiya Bykova, Andrey Sudarikov, Galina Gusarova, Vasily Shuvaev
Publikováno v:
Терапевтический архив, Vol 89, Iss 12, Pp 86-96 (2017)
To assess the results of following up patients with chronic myeloid leukemia (CML) and a deep molecular response (MR) without tyrosine kinase inhibitor (TKI) therapy.The reasons for TKI discontinuation in 70 patients with CML and a deep MR of more th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abcb16589145087e4367d94641c2ed19
https://doi.org/10.17116/terarkh2017891286-96
https://doi.org/10.17116/terarkh2017891286-96
Autor:
A. V. Novitskii, G. N. Bisaga, D. G. Polyntsev, Tyrenko Vv, M. S. Fominykh, Odinak Mm, P. V. Kruglyakov, A. A. Bilibina
Publikováno v:
Scopus-Elsevier
ResearcherID
ResearcherID
The safety and tolerance of treatment with autologous pluripotent mesenchymal stem cells (MSC) in multiple sclerosis were assessed in eight patients using autologous MSC harvested from the red bone marrow. MSC growth, immunophenotypes, and karyotypes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02fb605f85b8b4dd3a0f4c837522512a
https://doi.org/10.1007/s11055-012-9593-z
https://doi.org/10.1007/s11055-012-9593-z
Autor:
A G Turkina, E Yu Chelysheva, V A Shuvaev, G A Gusarova, A V Bykova, O A Shukhov, A N Petrova, M V Vakhrusheva, S R Goryacheva, L Yu Kolosova, P S Krasikova, M S Fominykh, I S Martynkevich, A O Abdullaev, A B Sudarikov, V G Savchenko
Publikováno v:
Терапевтический архив, Vol 89, Iss 12, Pp 86-96 (2017)
Aim. To assess the results of following up patients with chronic myeloid leukemia (CML) and a deep molecular response (MR) without tyrosine kinase inhibitor (TKI) therapy. Subjects and methods. The reasons for TKI discontinuation in 70 patients with
Externí odkaz:
https://doaj.org/article/a5d61a4d5cc34f2caccd0b415e5af767